A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing: The ASSESS Study - ASSESS

Astra Zeneca0 个研究点目标入组 120 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Provision of written informed consent.
•- Patients aged 18 years and older from European countries and patients aged 20 years and - older for patients from Japan.
•- Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not suitable for curative treatment or metastatic (stage IV) NSCLC.
•- Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are systemic treatment Naïve (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent disease who have previously received adjuvant chemotherapy (not including EGFR-TKI).
•- Provision of diagnostic cancer tissue or cytology sample upon inclusion (surgical specimen, biopsy sample, or cytology sample is acceptable).
•- Provision of a routine blood (plasma) sample.

•- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
•- Previous enrolment in the present study
•- As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
•- Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study.
•- Pregnancy or breast-feeding

发起方

Astra Zeneca